Menopausal Hormone Therapy And Left Ventricular Function (NCT07242391) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Menopausal Hormone Therapy And Left Ventricular Function
United States50 participantsStarted 2026-07
Plain-language summary
The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.
Who can participate
Age range45 Years ā 60 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
⢠\>45-60\< years of age
Exclusion Criteria
* Male sex
* Females between STRAW+10 stages -5 and 0
* PMF in STRAW+10 stage +2
* PMF using oral hormone therapy
* Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)
* Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction
* Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI.
* Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI.
* Pregnancy
* COPD
* Diabetes
* CKD
* Raynaud's phenomenon
* Sleep disorders
* Shift workers
* BMI ā„40.0kg/m2
* Use of nicotine-containing products within the two years preceding study visits
* Active cancer treatment